1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
CARB-X Funding Opportunities is a grant from CARB-X that funds preclinical research and development of antibacterial products targeting antimicrobial resistance (AMR). CARB-X supports small biotech companies, academic researchers, and nonprofit organizations worldwide working on therapeutics, preventatives, and diagnostics aligned with published Target Product Profiles.
Expressions of Interest for the 2026 funding round were accepted from April 8 to April 22, 2026. Eligibility and award amounts vary by funding theme; applicants must meet minimal entry criteria outlined in the Target Product Profiles. Applications are evaluated on scientific merit, and selected applicants proceed to full proposal submission through the CARB-X Portal.
Get alerted about grants like this
Get emailed when new opportunities from “CARB-X” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Applicants who have not yet applied will be first asked to register in the CARB-X Portal. To register and to submit an Expression of Interest, click on the button below. For technical assistance logging into the CARB-X Portal, please email carbxptl@bu.
edu . Target Product Profiles and minimal entry criteria for each theme can be found here . We highly encourage you to read our Frequently Asked Questions .
View the slides from the 2026 funding round webinars here . Expressions of Interest (EOI) for both themes may be submitted from 08 April 2026 at 10:00 ET to 22 April 2026 at 23:59 ET. In the EOI, you will be asked to answer a series of questions about your proposed project and will be given the opportunity to share pertinent, non-confidential details, in free text.
Your application will be judged on the merits of its scientific content; describe your science with as much data as possible. Please do provide sufficient data to allow a knowledgeable scientist to get a reasonable sense of the therapeutic/preventative/diagnostic. Do not provide other manuscripts, references, citations or similar.
Note that the form can only accept text; you may not enter tables or graphics. Do not include foundational information regarding the significance of antibiotic resistance; this is not necessary, as the reviewers understand this.
According to the current listing, eligibility includes: Small biotech companies, academic researchers, and nonprofits worldwide with preclinical AMR products; eligibility criteria vary by funding theme as outlined in Target Product Profiles. Confirm the full requirements in the official notice before applying.
The published deadline was April 22, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
CARB-X Funding Opportunities is funded by CARB-X. Verify program details on the funder's official page before applying.
This listing is flagged as international in scope. Check the official notice for country-specific restrictions before applying.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward interdisciplinary projects that leverage AI, machine learning, and advanced data science to address pressing questions in biomedical and public health research. It seeks to advance fundamental scientific and engineering contributions across disciplines to solve key health problems.